June 15, 2017
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ June 15, 2017]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that it has opened offices in Taipei, Taiwan and Tokyo, Japan. The offices are opened through the wholly-owned subsidiaries, CTI Clinical Trial and Consulting Services Taiwan and CTI Clinical Trial and Consulting Services Japan GK. The company has opened more than a dozen offices over the past few years, with additional international expansion planned in Asia over the next 6-12 months. The company established their Pacific-Asia headquarters in Sydney, Australia several years ago.
“The expansions in Taiwan and Japan are part of continued efforts to increase capacity for clinical research across Asia,” according to Patrick Earley, Vice President, International. “We have been working across Asia for a number of years, but felt like a more permanent presence in Taipei and Tokyo would further enhance relationships with local medical centers and biotechnology companies."
The company also announces the completion of their incorporation in Czech Republic under the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Czech Republic, s.r.o.
CTI has been working for nearly two decades in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve nearly 120 pharmaceutical, biotechnology, and medical device clients.
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com